Literature DB >> 14517793

Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors.

Anne-Marie Marion-Audibert1, Cécile Barel, Géraldine Gouysse, Jérôme Dumortier, Frank Pilleul, Céline Pourreyron, Valérie Hervieu, Gilles Poncet, Catherine Lombard-Bohas, Jean-Alain Chayvialle, Christian Partensky, Jean-Yves Scoazec.   

Abstract

BACKGROUND AND AIMS: In many malignant tumors, intratumoral microvascular density (MVD) has been suggested to be a prognostic parameter. We aimed to provide a quantitative evaluation of intratumoral microvascular density in a large series of resected endocrine tumors of the pancreas and to evaluate the potential prognostic significance of this parameter.
METHODS: Eighty-two tumors from 77 patients have been studied. MVD was evaluated by 2 observers after CD34 immunostaining and correlated with the following parameters: WHO classification, hormonal profile, tumor size, vascular endothelial growth factor expression, occurrence of metastasis, duration of survival.
RESULTS: MVD ranged from 5 to 92 vessels/field. MVD was significantly higher in well-differentiated benign endocrine tumors than in tumors of uncertain behavior and in carcinomas. No close correlation was found between MVD and the hormonal profile. MVD was significantly higher in tumors characterized by the following histoprognostic parameters: size <2 cm, proliferation index <2%, no evidence of metastasis. No close correlation was observed between MVD and VEGF expression. Finally, a MVD <30 vessels/field was associated with the occurrence of metastasis in tumors <2 cm and/or with a proliferation index <2% and with a significantly shorter survival after surgery.
CONCLUSIONS: The quantitative analysis of microvessel density in pancreatic endocrine tumors may identify patients who, despite favorable conventional histoprognostic factors, are at risk of unfavorable evolution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517793     DOI: 10.1016/s0016-5085(03)01198-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  30 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Xenon-inhalation computed tomography for noninvasive quantitative measurement of tissue blood flow in pancreatic tumor.

Authors:  Masaru Kubota; Takamichi Murakami; Hiroaki Nagano; Hidetoshi Eguchi; Shigeru Marubashi; Shogo Kobayashi; Hiroshi Wada; Masahiro Tanemura; Keizo Dono; Shoji Nakamori; Masato Sakon; Morito Monden; Masaki Mori; Yuichiro Doki
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

Review 3.  Relevance of angiogenesis in neuroendocrine tumors.

Authors:  Alexandre Teulé; Oriol Casanovas
Journal:  Target Oncol       Date:  2012-05-17       Impact factor: 4.493

4.  Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.

Authors:  E Belousova; G Karmazanovsky; A Kriger; D Kalinin; L Mannelli; A Glotov; N Karelskaya; O Paklina; A Kaldarov
Journal:  Clin Radiol       Date:  2016-11-24       Impact factor: 2.350

5.  Letter regarding "Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase".

Authors:  Shuai Ren; Zhongqiu Wang
Journal:  Abdom Radiol (NY)       Date:  2020-10-16

6.  Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.

Authors:  Feng Jin; Kai Wang; Ting-Ting Qin; Xin Li; Feng Guo; Gui-Na Ma; Xue-Han Hu; Ping Han
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

7.  Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Ming-Huang Chen; Yi-Chen Yeh; Yi-Ming Shyr; Yi-Hua Jan; Yee Chao; Chung-Pin Li; Shin-E Wang; Cheng-Hwai Tzeng; Peter Mu-Hsin Chang; Chun-Yu Liu; Ming-Han Chen; Michael Hsiao; Chi-Ying F Huang
Journal:  J Gastroenterol       Date:  2012-06-16       Impact factor: 7.527

8.  Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Authors:  Yanji Luo; Zhi Dong; Jie Chen; Tao Chan; Yuan Lin; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2014-07-22       Impact factor: 5.315

9.  Contrast-enhanced harmonic endoscopic ultrasound using time-intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm.

Authors:  Saimon Takada; Hironari Kato; Yosuke Saragai; Shinichiro Muro; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Noriyuki Tanaka; Hiroyuki Okada
Journal:  J Med Ultrason (2001)       Date:  2019-08-03       Impact factor: 1.314

10.  Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; So Yeon Kim; Ki Byung Song; Nikhil H Ramaiya; Sree Harsha Tirumani; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.